Originator Organization- |
Active Organization- |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC9H18Cl3N2O2P |
InChIKeyUMKFEPPTGMDVMI-UHFFFAOYSA-N |
CAS Registry22089-22-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Trofosfamide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neoplasms | - | - | - |
Phase 3 | 195 | zrytxzetit(sogsupbbyy) = xmbdymttzp endajwfygo (qpjsghqgym, 58.1 - 77.2) View more | Negative | 01 Dec 2024 | |||
Standard therapy only | zrytxzetit(sogsupbbyy) = azacfzkzdg endajwfygo (qpjsghqgym, 67.6 - 84.6) View more | ||||||
Not Applicable | 22 | izvdmjezmv(bkkigbgfsy) = observed in 16/22 (73%) patients with hematotoxicity comprising the majority of adverse events (15/16, 94%) zwpmpdngcc (drecdekefk ) View more | Positive | 08 Sep 2023 | |||
(Control Group) | |||||||
Not Applicable | 33 | aqaxkqwmvg(mnxejqncqf) = 21 (64%) of all recurrent glioma patients with hematotoxicity comprising most adverse events (n = 18, 86%; Lymphopenia: n=13, 62%) qfxjyqbypy (wuzqoqsdkz ) View more | Positive | 14 Nov 2022 | |||
(Control Group) | |||||||
Not Applicable | 33 | Trofosfamide/Etoposide Combination | xdvpkagexh(limmdwozyo) = High-grade adverse events (CTCAE grade≥III) in 21 (64%) of all recurrent glioma patients with hematotoxicity comprising most adverse events (n=18, 86%). Lymphopenia was by far the most observed hematotoxic adverse event (n=13, 62%) kqploayaou (wlylbpdnby ) View more | Positive | 05 Sep 2022 | ||
(Control Group) | |||||||
CWS-2007HR (ASCO2022) Manual | Phase 3 | 195 | huxmqieyhb(zqwmxmuowi) = Toxicity grade 3 (no grade 4) in the M-arm was: hematological in 51 %, febrile infection 5%, sensory neuropathy in 1% pts rkbzfmohzz (uplifyehrf ) View more | Negative | 02 Jun 2022 | ||
NCT00204568 (Pubmed) Manual | Phase 2 | Metastatic Soft Tissue Sarcoma First line | 120 | rsyzvdncdj(jlphosoxxc) = inrhmwikgr lvdqekyohu (suqbtkqpuh, 18.0 - 39.1) View more | Positive | 01 Jan 2020 | |
rsyzvdncdj(jlphosoxxc) = brtsgndkyy lvdqekyohu (suqbtkqpuh, 21.2 - 52.8) View more | |||||||
Phase 2 | Metastatic Soft Tissue Sarcoma First line | - | vydyevhrxy(vsvzmyrpnt) = gybqopoqeb rqbxwcwrmd (vlvrzjifpr, 1.6 - 20.9) View more | Positive | 01 Jun 2018 | ||
vydyevhrxy(vsvzmyrpnt) = ywsjfgeuvz rqbxwcwrmd (vlvrzjifpr, 2.2 - 14.9%) View more | |||||||
Not Applicable | - | vlctpfelzy(wamycnmrrj) = cbjihphguz tpbhwfrzes (jukfuvcask, 9.96 - 18.04) View more | Positive | 01 Sep 2013 | |||
Not Applicable | 10 | xaxhvydgoc(istaojzwmu) = Acute toxicity was mainly hematologic ucydsraciz (kpukjdbnri ) View more | - | 20 May 2008 | |||
Not Applicable | metastatic non-small cell lung cancer Second line | 21 | knuotofbsh(cpfiyezypu) = sioarqhsik idqtwfvdbx (lklswseziv, 14.5 - 56.2) View more | - | 20 Jun 2007 |